TBPH · As filed with the SEC
Theravance Biopharma cash flow statement, by fiscal year
The statement as Theravance Biopharma presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED STATEMENTS OF CASH FLOWS · USD
| USD | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 |
|---|---|---|---|---|
| Operating activities | ||||
| Net loss | — | (56,418,000) | (55,193,000) | 872,132,000 |
| Less: Net income from discontinued operations | — | — | — | (964,956,000) |
| Net loss from continuing operations | — | — | (55,193,000) | (92,824,000) |
| Net income (loss) | 105,895,000 | — | — | — |
| Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | ||||
| Depreciation and amortization | 1,626,000 | 1,710,000 | 2,001,000 | 3,716,000 |
| Amortization and accretion on investment securities, net | (2,830,000) | (2,509,000) | (1,897,000) | (681,000) |
| Future royalty payment contingency interest accretion | 2,461,000 | 2,546,000 | 2,350,000 | 974,000 |
| Share-based compensation | 18,476,000 | 21,393,000 | 25,371,000 | 39,734,000 |
| Gain on sale of Velusetrag | — | — | — | (2,709,000) |
| Loss on disposal of property and equipment | 35,000 | 34,000 | 1,352,000 | (8,000) |
| Loss on impairment of long-lived assets | — | 4,513,000 | — | — |
| Loss on impairment of long-lived assets | 0 | — | — | — |
| Amortization of right-of-use assets | 4,015,000 | 4,414,000 | 4,152,000 | 3,989,000 |
| Deferred income taxes | — | (7,573,000) | 3,207,000 | — |
| Loss on extinguishment of debt | — | — | — | 3,034,000 |
| Deferred income taxes | (11,519,000) | — | — | — |
| Other | (89,000) | — | — | — |
| Changes in operating assets and liabilities: | ||||
| Receivables from collaborative and licensing arrangements | (27,099,000) | (966,000) | (689,000) | (2,720,000) |
| Prepaid clinical and development services | 73,000 | 1,965,000 | (526,000) | 8,733,000 |
| Other prepaid and current assets | (3,360,000) | 7,399,000 | (3,921,000) | (704,000) |
| Right-of-use lease assets | (32,000) | (707,000) | (314,000) | (4,424,000) |
| Future contingent milestone and royalty assets | 144,200,000 | — | — | — |
| Other assets | (1,077,000) | 411,000 | (1,233,000) | (3,802,000) |
| Accounts payable | 326,000 | 750,000 | 6,000 | (1,612,000) |
| Accrued personnel-related expenses, accrued clinical and development expenses, and other accrued liabilities | 4,009,000 | 1,468,000 | (7,095,000) | (14,086,000) |
| Accrued interest payable | — | — | — | (1,246,000) |
| Deferred revenue | — | — | (216,000) | (192,000) |
| Operating lease liabilities | (7,117,000) | 661,000 | (3,001,000) | (1,024,000) |
| Unrecognized tax benefits | 10,481,000 | 9,906,000 | 1,102,000 | 63,952,000 |
| Other long-term liabilities | 67,000 | (532,000) | 7,547,000 | (525,000) |
| Net cash used in operating activities - continuing operations | — | — | (26,997,000) | (2,425,000) |
| Net cash used in operating activities - discontinued operations | — | — | — | (184,566,000) |
| Net cash provided by (used in) operating activities | 238,541,000 | (11,535,000) | (26,997,000) | (186,991,000) |
| Investing activities | ||||
| Purchases of property and equipment | (42,000) | (332,000) | (2,488,000) | (572,000) |
| Purchases of marketable securities | (248,217,000) | (140,743,000) | (134,534,000) | (103,145,000) |
| Maturities of marketable securities | 142,975,000 | 139,813,000 | 31,435,000 | 158,000,000 |
| Purchase of derivative | — | (2,292,000) | — | — |
| Sale of short-term investments and marketable securities | — | 15,838,000 | 71,377,000 | 17,000 |
| Proceeds from the sale of Velusetrag | — | — | — | 2,709,000 |
| Proceeds from the sale of property and equipment | — | — | 1,513,000 | 1,866,000 |
| Net cash (used in) provided by investing activities - continuing operations | — | — | (32,697,000) | 58,875,000 |
| Net cash provided by investing activities - discontinued operations | — | — | — | 1,095,134,000 |
| Net cash (used in) provided by investing activities | (105,284,000) | 12,284,000 | (32,697,000) | 1,154,009,000 |
| Financing activities | ||||
| Ordinary share repurchases | — | (445,000) | (197,051,000) | (128,830,000) |
| Proceeds from ampreloxetine funding, net | — | — | — | 24,464,000 |
| 9.5% Non-Recourse Notes Due 2035 | — | — | — | (399,998,000) |
| 3.25% Convertible Senior Notes Due 2023 | — | — | — | (231,605,000) |
| Proceeds from the sale of ordinary shares | 20,000 | 99,000 | — | — |
| Proceeds from ESPP purchases | — | 508,000 | 618,000 | 802,000 |
| Proceeds from option exercises | 766,000 | — | — | — |
| Repurchase of shares to satisfy tax withholding | (4,034,000) | (2,659,000) | (2,500,000) | (3,450,000) |
| Net cash used in financing activities - continuing operations | — | — | (198,933,000) | (738,617,000) |
| Net cash used in financing activities - discontinued operations | — | — | — | (20,189,000) |
| Net cash used in financing activities | (3,248,000) | (2,497,000) | (198,933,000) | (758,806,000) |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 130,009,000 | (1,748,000) | (258,627,000) | 208,212,000 |
| Cash, cash equivalents, and restricted cash at beginning of period | 38,633,000 | 40,381,000 | 299,008,000 | 90,796,000 |
| Cash, cash equivalents, and restricted cash at end of period | 168,642,000 | 38,633,000 | 40,381,000 | 299,008,000 |
| Supplemental disclosure of cash flow information | ||||
| Interest Expense | — | — | — | 22,244,000 |
| Cash paid for income taxes, net | 27,884,000 | 109,000 | 24,000 | 117,966,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.